Trials / Unknown
UnknownNCT03029858
PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients
Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 155 (estimated)
- Sponsor
- Guangdong Association of Clinical Trials · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced epidermal growth factor receptor （EGFR）T790M positive advanced NSCLC patients. In addition, we will explore whether PD-L1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of PD due to osimertinib resistance.
Detailed description
Investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced EGFR T790M positive advanced NSCLC patients. explore whether PD-L1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of PD due to osimertinib resistance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No interventions will be taken in this Observational study | TAGRISSO(osimertinib/AZD9291） |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2020-09-01
- Completion
- 2020-09-01
- First posted
- 2017-01-24
- Last updated
- 2017-01-24
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03029858. Inclusion in this directory is not an endorsement.